1. Pantazou, V., Schluep, M. & Du Pasquier, R. Environmental factors in multiple sclerosis. Press. Medicale 44, e113–e120 (2015).
2. Sicras-Mainar, A., Ruíz-Beato, E., Navarro-Artieda, R. & Maurino, J. Comorbidity and metabolic syndrome in patients with multiple sclerosis from Asturias and Catalonia, Spain. BMC Neurol. 17, 1–6 (2017).
3. Marrie, R. A. Comorbidity in multiple sclerosis: Past, present and future. Clin. Invest. Med. 42, E5–E12 (2019).
4. Munger, K. L., Chitnis, T. & Ascherio, A. Body size and risk of MS in two cohorts of US women. Neurology 73, 1543–1550 (2009).
5. Ben-zacharia, A. B. The Effects of Body Mass Index ( BMI ) on Multiple Sclerosis ( MS ) Progression. Ann. Mult. Scler. Res. 1, 1–7 (2018).
6. Dendrou, C. A., Fugger, L. & Friese, M. A. Immunopathology of multiple sclerosis. Nat. Rev. Immunol. 15, 545–558 (2015).
7. Watson, G. S. & Craft, S. Insulin resistance, inflammation, and cognition in Alzheimer’s Disease: Lessons for multiple sclerosis. J. Neurol. Sci. 245, 21–33 (2006).
8. Styskal, J., Van Remmen, H., Richardson, A. & Salmon, A. B. Oxidative stress and diabetes: What can we learn about insulin resistance from antioxidant mutant mouse models? Free Radic. Biol. Med. 52, 46–58 (2012).
9. Oliveira, S. R. et al. Disability in patients with multiple sclerosis: Influence of insulin resistance, adiposity, and oxidative stress. Nutrition 30, 268–273 (2014).
10. Lee, C. et al. HHS Public Access. 21, 443–454 (2016).
11. Du, C. et al. Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance. Pediatr. Diabetes 19, 1058–1064 (2018).
12. Baylan, F. A. & Yarar, E. Relationship between the mitochondria-derived peptide MOTS-c and insulin resistance in obstructive sleep apnea. Sleep Breath. (2021). doi:10.1007/s11325-020-02273-0
13. Ramanjaneya, M. et al. Lipids and insulin regulate mitochondrial-derived peptide (MOTS-c) in PCOS and healthy subjects. Clin. Endocrinol. (Oxf). 91, 278–287 (2019).
14. Qin, Q. et al. Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction. Int. J. Cardiol. 254, 23–27 (2018).
15. Cataldo, L. R., Fernández-Verdejo, R., Santos, J. L. & Galgani, J. E. Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals. J. Investig. Med. 66, 1019–1022 (2018).
16. Lu, H., Koshkin, V., Allister, E. M., Gyulkhandanyan, A. V. & Wheeler, M. B. Molecular and metabolic evidence for mitochondrial defects associated with β-cell dysfunction in a mouse model of type 2 diabetes. Diabetes 59, 448–459 (2010).
17. Ramanjaneya, M. et al. Mitochondrial-derived peptides are down regulated in diabetes subjects. Front. Endocrinol. (Lausanne). 10, 1–10 (2019).
18. Krogh-Madsen, R., Plomgaard, P., Keller, P., Keller, C. & Pedersen, B. K. Insulin stimulates interleukin-6 and tumor necrosis factor-α gene expression in human subcutaneous adipose tissue. Am. J. Physiol. - Endocrinol. Metab. 286, 234–238 (2004).
19. Kim, S. J. et al. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiol. Rep. 7, 1–12 (2019).
20. Salinari, S. et al. Dodecanedioic acid overcomes metabolic inflexibility in type 2 diabetic subjects. Am. J. Physiol. - Endocrinol. Metab. 291, 1051–1059 (2006).
21. Lee, C., Kim, K. H., Cohen, P., Angeles, L. & States, U. Muscle and Fat Metabolism. 182–187 (2016). doi:10.1016/j.freeradbiomed.2016.05.015.MOTS-c
22. Hauser, S. L. & Cree, B. A. C. Treatment of Multiple Sclerosis: A Review. Am. J. Med. 133, 1380-1390.e2 (2020).
23. Wei, M. et al. Mitochondrial-Derived Peptide MOTS-c Attenuates Vascular Calcification and Secondary Myocardial Remodeling via Adenosine Monophosphate-Activated Protein Kinase Signaling Pathway. CardioRenal Med. 10, 42–50 (2020).